ASGT Annual Meeting

Program

ASGT 6th Annual Meeting
June 4-8, 2003, Washington, D.C.
Jointly sponsored by Baylor College of Medicine, Houston, Texas

Program Schedule

Friday, June 6
7:00 am - Noon	Poster Setup by Authors
7:30 am - 5:00 pm	Attendee Registration Open
8:00 am - 10:00 am	Scientific Symposia
	SS300 - Cardiovascular: New Concepts in Gene and Cell Therapy in Cardiovascular Disorders Salon 1 Chair Ralph Kelly, MD Speakers Ralph Kelly, MD - HIF-1 and Therapeutic Angiogenesis J. Kevin Donahue, MD - Gene Therapy for Cardiac Arrhythmias Doris A. Taylor, PhD - Cell Transplantation for Cardiac Repair: Where are We?
	SS301 - Special: Young Investigators Symposium Cotillion North & South The American Society of Gene Therapy is pleased to announce the recipients of the new Young Investigator Awards. These Three Outstanding Young Investigators were chosen based on their contributions to the field of gene therapy in 2002/2003. Each of the awardees will give a presentation of their work. Chair Savio L.C. Woo, PhD Speakers Alessandro Aiuti, MD, PhD Roland W. Herzog, PhD Christof von Kalle, MD
	SS302 - Hemopoietic: Retrovirus Insertional Mutagenesis Salon 2/3 Chair Carolyn Wilson, PhD Speakers Frederic D. Bushman, PhD - HIV DNA Integration Christopher Baum, MD - Retroviral Vectors: Therapeutic Mutagens? Shawn Burgess, PhD - Watch Where You Land: Different Global Genomic Preferences for MLV and HIV-1 Proviral Integration
	SS303 - Viral: Intracellular Trafficking of Viruses Maryland Room Chair Michael J. Imperiale, PhD (696, USA) Speakers Nicholas Muzyczka, PhD - Intracellular Trafficking of rAAV and Identification of the Receptor Binding Site on the Viral Surface Didier Trono, MD - Immediate Early Phase of Retroviral Infection: Overcoming an Intracellular Innate Antiviral Response Lynn W. Enquist, PhD - Alpha Herpes Virus Infection of the Mammalian Nervous System
10:00 am - 10:15 am	Break
10:15 am - 12:15 pm	Scientific Symposia
	SS310 - Cancer: Systemic Cancer Gene Therapy Salon 2/3 Chair David T. Curiel, MD, PhD Speakers Carl H. June, MD - Use of Lentiviral Modified T-Cells for Immunotherapy Ian MacLachlan, PhD - Disease Site Targeting, Tumor Specific Gene Expression and Anti-Tumor Efficacy of Stable Plasmid-Lipid Particles for Systemic Gene Delivery Michael Andreeff, MD, PhD - Gene-Modified Non-Hematopoietic Bone Marrow Stem Cells as Delivery Systems of Therapeutic Genes in Cancer and Leukemia Sunil Chada, PhD - The mda-7 Gene Encodes Both Tumor Suppressor and TH1 Cytokine (IL-24) Activities: Prospects for Systemic Therapy
	SS311 - Musculo-Skeletal: Gene Therapy for Bone and Cartilage Defects Salon 1 Chair Johnny Huard, PhD Speakers Johnny Huard, PhD - Gene Therapy Based on Muscle Derived Stem Cells: Potential for Musculo-Skeletal Tissue Regeneration Jay R. Lieberman, MD - Regional Gene Therapy to Enhance Bone Repair Rocky Tuan, PhD - Skeletal Tissue Engineering Applications of Multipotential Mesenchymal Stem Cells Derived from Adult Human Tissues Darwin J. Prockop, MD, PhD - Characterizations of the Expansion and Reparative Properties of Adult Stem Cells from Bone Marrow
	SS312 - Neural Disorders: Translating Basic Research to the Clinic Cotillion Ballroom North & South Chair David J. Fink, MD Speakers Mark H. Tuszynski, MD, PhD - Growth Factor Gene Therapy for Neurodegenerative Disorders Michael Kaplitt, MD, PhD - AAV-mediated Gene Therapy for Neurodegenerative Disorders David J. Fink, MD - HSV-mediated Gene Transfer for Pain and Neuropathy: The Right Vector for the Right Disease
	SS313 - Respiratory Tract: Gene Therapy to Protect Lung Against Infection and Emerging Pathogens Maryland Room Chair Jay K. Kolls, MD Speakers Jay K. Kolls, MD - Gene-based Immunotherapy Against Lung Infection Joanne L. Flynn, PhD - Mycobacterium Tuberculosis: The Immunologic Environment of the Lung During Infection Alistair Ramsay, PhD - Combination Vector-based Gene Delivery for Enhanced Pulmonary Immunity Ronald G. Crystal, MD - Enhancing DC Function to Combat Emerging Infections
Noon - 7:00 pm	Poster Viewing
12:30 pm - 1:30 pm	Meet-the-Expert Lunches The Meet-the-Expert sessions are designed to provide an opportunity for participants to interact with experts and discuss topics related to their research. A lunch will be served during the program, which will begin at 12:30 pm and last for approximately one hour. The Meet-the-Expert sessions require tickets for admission. Tickets for these sessions are not included in the regular registration fees to attend the meeting. Ushers will be collecting tickets at the door of each session. Tickets are available at the registration desk. Please note that space is limited.
	ME320 - Gene Therapy for Bleeding Disorders Park Tower 8212 Katherine A. High, MD
	ME321 - Non-Viral Vectors: Looking Into the Future Park Tower 8216 Leaf Huang, PhD
	ME322 - Hydrodynamic Gene Delivery Park Tower 8219 Dexi Liu, PhD
	ME323 - Everything You Wanted to Know About AAV Vectors McKinley Room Nicholas Muzyczka, PhD
	ME324 - FDA: Talk to Us! Harding Room Philip D. Noguchi, MD
	ME325 - Gene Therapy Approaches for Inherited Metabolic Diseases Coolidge Room Mark S. Sands, PhD
	ME326 - Plasmid Based Cancer Gene Therapy Hoover Room Sean M. Sullivan, PhD
1:45 pm - 4:15 pm	Simultaneous Oral Presentations
	OA330 - Advances in Technology and Applications Marriott Ballroom Salon 2/3 Moderators Lung-Ji Chang, PhD Derek Persons, MD, PhD (Abstracts #380 - #389)
	OA331 - Advances in Gene Therapy for Hematologic Disorders Virginia Moderators C. Anthony Blau, MD Fabio Candotti, MD (Abstracts #390 - #399)
	OA332 - Vector Genome Biology Marriott Ballroom Salon I Moderators Guangping Gao, PhD Xiao Xiao, PhD (Abstracts #400 - #409)
	OA333 - Novel Ad Vectors - Ad Receptors Maryland Moderators Sheila Connelly, PhD Victor W. Van Beusechem, PhD (Abstracts #410 - #419)
	OA334 - Lipid Mediated Transfer Washington Room 4 Moderators Ralph W. Paul, PhD Nancy Smyth Templeton, PhD (Abstracts #420 - #427)
	OA335 - Cancer Immunotherapy Cotillion North Moderators Leisha A. Emens, MD, PhD Stephen L. Eck, MD, PhD (Abstracts #428 - #435)
	OA336 - Cancer Targeted Gene Therapy II Cotillion South Moderators Dale Ando, MD Robin J. Parks, PhD (Abstracts #436 - #443)
3:00 pm - 7:00 pm	Exhibit Hall Open
4:00 pm - 7:00 pm	Poster Session II Poster Session, Exhibits and Networking Reception Halls B/C
	RNA Virus Vectors II (Abstracts #444 through #469) Applications in Disease (Abstracts #470 through #490) Novel Ad Vectors and Applications (Abstracts #491 through # 531) Lipid Mediated Gene Transfer (Abstracts #532 through 566) Molecular Conjugates: New Technologies (Abstracts #567 through #580) Cardiovascular (Abstracts #581 through #633) Gene Therapy for the Nervous System II (Abstracts #634 through #659) Infectious Diseases and Vaccines (Abstracts #660 through #692) Cancer Vaccines (Abstracts #693 through #718) Oncolytic Virus and Suicide Gene Therapy for Cancer (Abstracts #719 through #744) Cancer Targeted Gene Therapy II (Abstracts #745 through #773) Gene Regulation: Technology and Applications (Abstracts #774 through #804)
7:00 pm - 10:00 pm	Corporate Symposium CS340 Oncolytic Adenoviruses as Cancer Therapeutics: Challenges in Product Development Supported by Cell Genesys, Inc. Oncolytic viruses are a novel class of cancer therapeutics designed to turn the lytic power of viruses against tumors by restricting viral replication to tumor cells. Approximately 80 different virus variants have been tested for antitumor efficacy in animals or humans, including a Phase III study of an oncolytic adenovirus in patients with local refractory head and neck cancer. The objective of this symposium is to discuss challenges in the product development of selectively replicating oncolytic viruses focusing specifically on oncolytic adenoviruses, which comprise many of the most clinically advanced products. After a detailed overview of the current state of the field is presented, speakers will focus on issues including product release criteria (e.g., quantification of viral titer, wild type contamination and tumor selectivity), manufacturing controls, relevant preclinical safety studies, and clinical trial study design and control. A final presentation will discuss research to produce second-generation oncolytic viruses with improved selectivity and efficacy, including advances in transcriptional and transductional targeting, immunological shielding, and systemic delivery. Co-Chairs Shirley M. Clift, BA De Chao Yu, PhD Speakers Russette M. Lyons, PhD - Oncolytic Adenoviruses Today: Past the Beginning Andrew Byrnes, PhD - Manufacturing and Testing of Oncolytic Adenoviruses Joy Cavagnaro, PhD, DABT, RAC - The Design of Preclinical Safety Studies to Support Clinical Decision Making David H. Kirn, MD - Clinical Trials with Replication-Selective Oncolytic Adenoviruses: What Have We Learned? David T. Curiel, MD, PhD - Advanced Design Approaches to Realize the Therapeutic Potential of Conditionally Replication Competent Adenoviral Agents Shirley M. Clift, BA - Wrap-up and Overview De Chao Yu, PhD - Wrap-up and Overview